Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
Carisma Therapeutics (CARM) Stock Price & Analysis
1,476 Followers
CARM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.53 - $9.77
Previous Close$1.7
Volume54.73K
Average Volume (3M)168.97K
Market Cap
$70.62M
Enterprise Value-$3.86M
Total Cash (Recent Filing)$77.61M
Total Debt (Recent Filing)$3.12M
Price to Earnings (P/E)-0.5
Beta1.44
Next Earnings
May 09, 2024EPS EstimateN/A
Last Dividend Ex-Date
Mar 08, 2023Dividend Yield425.26%
Share Statistics
EPS (TTM)-3.47
Shares Outstanding41,542,534
10 Day Avg. Volume169,214
30 Day Avg. Volume168,967
Standard Deviation0.30
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.63
Price to Sales (P/S)0.82
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.04
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$8.75Price Target Upside433.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Carisma Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCarisma Therapeutics is advancing its novel CAR-engineered macrophages with lead therapeutic showing promise in solid tumor treatment and potential in reversing fibrosis.
Clinical TrialsInitial clinical data suggests that CT-0508 in combination with pembro is encouraging for treating solid tumors, offering hope for patients with refractory cancer.
Strategic PartnershipsCompelling data from Carisma's fibrosis program could attract strategic partnerships, enhancing the company's growth prospects in non-oncology fields.
Bears Say
Corporate DownsizingCARM announced a reduction in workforce by 37%, which may signal cost-cutting measures due to financial constraints.
Drug Efficacy ConcernsTwo patients in the study had low grade cytokine release syndrome and were treated with corticosteroids, which diminishes CT-0508 activity.
Pipeline SetbacksCARM is ceasing further development of its lead candidate, CT-0508, and prioritizing CT-0525, which has not yet entered the clinic.
---
Ownership Overview
61.91%
Insiders
6.40% Mutual Funds
6.36% Other Institutional Investors
25.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $1.53 and its highest was $9.77 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Currently, no data Available
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 12 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Apr 01, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.432 by -$0.088.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.36 which represents an annual dividend yield of 425.26%. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,542,534 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.432. Following the earnings report the stock price went down -7.93%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Among the largest hedge funds holding Carisma Therapeutics’s share is Hussman Strategic Advisors Inc. It holds Carisma Therapeutics’s shares valued at N/A.
---
Carisma Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (433.54% Upside)
$8.75 (433.54% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.79%
12-Months-Change
Fundamentals
Return on Equity
-94.06%
Trailing 12-Months
Asset Growth
-67.03%
Trailing 12-Months
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Months Forecast
Average Price Target
$8.75
▲(433.54% Upside)
Technical Analysis
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-51.23%
reiterated a buy rating 16 days ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.23% per trade.
---